KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Fulgent Genetics (FLGT) EBIT (2016 - 2026)

Fulgent Genetics' EBIT history spans 12 years, with the latest figure at -$34.6 million for Q1 2026.

  • On a quarterly basis, EBIT fell 74.9% to -$34.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$70.2 million, a 2.41% increase, with the full-year FY2025 number at -$14.7 million, up 80.11% from a year prior.
  • EBIT hit -$34.6 million in Q1 2026 for Fulgent Genetics, down from -$500000.0 in the prior quarter.
  • Over the last five years, EBIT for FLGT hit a ceiling of $201.9 million in Q1 2022 and a floor of -$151.1 million in Q4 2023.
  • Historically, EBIT has averaged -$8.4 million across 5 years, with a median of -$17.1 million in 2024.
  • Biggest five-year swings in EBIT: crashed 18990.12% in 2023 and later soared 96.9% in 2025.
  • Tracing FLGT's EBIT over 5 years: stood at $800000.0 in 2022, then crashed by 18990.12% to -$151.1 million in 2023, then skyrocketed by 89.32% to -$16.1 million in 2024, then soared by 96.9% to -$500000.0 in 2025, then tumbled by 6824.4% to -$34.6 million in 2026.
  • Business Quant data shows EBIT for FLGT at -$34.6 million in Q1 2026, -$500000.0 in Q4 2025, and -$15.4 million in Q3 2025.